Alphatec Holdings Inc (ATEC), a spine-focused medical technology company, and Theradaptive Inc, a clinical-stage regenerative medicine innovator, have entered into a definitive strategic partnership to advance next-generation biologic solutions for spine surgery.

As part of the agreement, Alphatec has secured exclusive commercial rights in the United States to market and distribute Theradaptive’s OsteoAdapt osteoinductive bone graft for spinal fusion. The collaboration marks a significant milestone for regenerative medicine in the spine sector and is structured to deliver long-term value through upfront payments, development and commercial milestones, and a perpetual royalty arrangement.

OsteoAdapt is built on Theradaptive’s proprietary AMP2 engineered protein technology and is currently being evaluated in clinical trials for spine and dental applications. The product is subject to US Food and Drug Administration Premarket Approval and has already received three FDA Breakthrough Device Designations, highlighting its potential to address substantial unmet needs in bone regeneration.

Pat Miles, chairman and chief executive officer of Alphatec, said the partnership strengthens the company’s procedural ecosystem by adding a long-sought biologic solution to its spine platform. He noted that integrating OsteoAdapt into Alphatec’s Organic Innovation Machine positions the company to meaningfully improve fusion outcomes and set a new benchmark for clinical differentiation in spine surgery.

In parallel with the partnership, Theradaptive announced the launch of a Series B financing round. The funding is intended to support completion of clinical studies, advance the OASIS pivotal spinal fusion trial, and scale manufacturing capabilities in preparation for future commercialisation alongside Alphatec.

Luis Alvarez, founder and chief executive officer of Theradaptive, said the collaboration with Alphatec, combined with the Series B raise, provides both the commercial reach and capital required to bring its engineered protein platform to patients globally and accelerate a new era in regenerative medicine.

The partnership targets a sizeable market opportunity, with the US spine surgery market valued at over USD 10 billion annually and biologics accounting for more than USD 2 billion. OsteoAdapt’s targeted regenerative approach is positioned as a potential alternative to traditional allograft and synthetic options, with Alphatec’s expanding sales infrastructure expected to drive adoption and market penetration.

Alphatec Holdings, through its subsidiaries including Alphatec Spine, EOS Imaging, and SafeOp Surgical, focuses on advancing spine surgery through integrated informatics, imaging, navigation and instrumentation. Theradaptive develops targeted protein therapeutics across spine, orthopaedics, dental and soft tissue repair, leveraging its delivery platform to address critical unmet medical needs. OsteoAdapt SP remains an investigational device limited to investigational use under US federal law.